U.S. CDC Advisory Committee On Immunization Practices Recommends Booster Vaccination With Moderna's COVID-19 Vaccine.
Moderna Gets FDA Authorization of Booster Dose of Covid-19 Vaccine.
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older.
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries- meaning we got paid.
Moderna's Cytomegalovirus ("CMV") vaccine is phase 3 trial ready, and there are no approved vaccines for CMV currently, handing Moderna a potential first mover advantage in a multi-billion dollar market. Cytomegalovirus infects the majority of people over the course of their lifetime, with most asymptomatic, so it will be interesting to see what kind of revenues a CMV vaccine could earn, but Moderna itself views the opportunity as $2 - $5bn.
Moderna also has a Zika vaccine in Phase 2 trials, Respiratory Syncytial Virus ("RSV") and Influenza vaccines being prepped for a Phase 2/3 trial, and a COVID / Influenza combo, HIV, Nipah and Epstein Barr vaccines at earlier stages of development.
There is every chance that $(Moderna)$ can become a major player in almost every vaccine market.
精彩评论